Pembrolizumab for the treatment of relapsed and refractory classical hodgkin lymphoma after autologous transplant and in transplant-naive patients

被引：0
|
作者：
Halahleh, K. [1 ]
Muradi, I. [2 ]
Al-Sawajneh, S. [1 ]
Saleh, Y. [1 ]
Barakat, F. [1 ]
Sultan, I. [1 ]
机构：
[1] King Hussein Canc Ctr & Fdn, Amman, Jordan
[2] Al Ahliyya Amman Univ, Al Salt, Jordan
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P430
引用
收藏
页码：333 / 334
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naive Patients
    Halahleh, Khalid
    Al Sawajneh, Suhaib
    Saleh, Yacob
    Shahin, Omar
    Abufara, Alaa
    Ma'koseh, Mohamad
    Abdel-Razeq, Rashid
    Barakat, Fareed
    Abdelkhaleq, Hadeel
    Al-Hassan, Nadira
    Atiyyat, Reem
    Al-Faker, Noor
    Omari, Zaid
    Ghatasheh, Hamza
    Jaradat, Imad
    Muradi, Isa
    Iyad, Sultan
    Bazarbachi, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : 589 - 595
  • [2] Brentuximab Vedotin in Transplant-Naive Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Cantonetti, Maria
    Re, Alessandro
    Pinto, Antonello
    Pavone, Vincenzo
    Rigacci, Luigi
    Celli, Melania
    Broccoli, Alessandro
    Argnani, Lisa
    Pulsoni, Alessandro
    ONCOLOGIST, 2015, 20 (12): : 1413 - 1416
  • [3] Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
    Sasse, Stephanie
    Rothe, Achim
    Goergen, Helen
    Eichenauer, Dennis A.
    Lohri, Andreas
    Kreher, Stephan
    Jaeger, Ulrich
    Bangard, Christopher
    Kuhnert, Georg
    Boell, Boris
    von Tresckow, Bastian
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2144 - 2148
  • [4] Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies
    Forero-Torres, Andres
    Fanale, Michelle
    Advani, Ranjana
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Kennedy, Dana A.
    Younes, Anas
    ONCOLOGIST, 2012, 17 (08): : 1073 - 1080
  • [5] Autologous Stem Cell Transplant Is a Feasible Treatment For Older Relapsed and Refractory Hodgkin Lymphoma Patients
    Glick, Hillary
    Lee, Connie
    Sauter, Craig S.
    Moskowitz, Craig H.
    Matasar, Matthew J.
    BLOOD, 2013, 122 (21)
  • [6] Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
    Mehta-Shah, Neha
    Bartlett, Nancy L.
    BLOOD, 2018, 131 (15) : 1698 - 1703
  • [7] Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
    Baron, Kelsey
    Drill, Esther
    Ganesan, Nivetha
    Merryman, Reid W.
    Mei, Matthew G.
    Stuver, Robert
    Desai, Sanjal H.
    Falade, Ayo S.
    Iyengar, Siddharth
    Micallef, Ivana
    Ng, Lay She
    Casper, Ellie
    Galasso, Natasha
    Tao, Randa
    Dandapani, Savita
    Ng, Andrea
    Yahalom, Joachim
    Herrera, Alex F.
    Moskowitz, Alison
    Shah, Harsh
    BLOOD, 2023, 142
  • [8] Consolidation Therapy After Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma
    O'Brien, Susan
    Moskowitz, Craig H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (09) : 662 - 664
  • [9] THE SURVIVAL OF RELAPSED/REFRACTORY PATIENTS WITH HODGKIN'S LYMPHOMA TREATED WITH ALLOGENEIC TRANSPLANT IS NOT IMPACTED BY THE TIME OF RELAPSE AFTER AUTOLOGOUS TRANSPLANT OR REFRACTORY DISEASE
    Spina, F.
    Dalto, S.
    De Philippis, C.
    Viviani, S.
    Corradini, P.
    HAEMATOLOGICA, 2015, 100 : 7 - 7
  • [10] Pembrolizumab and allotransplants for relapsed refractory classical hodgkin lymphoma
    Halahleh, K.
    Muradi, I.
    Al-Rimawi, D.
    Ma'koseh, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 203 - 204
12345